Fabbri, Alberto <br/><br/>
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.  [electronic resource] 

 -  Hematological oncology  Dec 2013 
 - 213-7 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1099-1069 
<br/><br/><label>Standard No.: </label>10.1002/hon.2038  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Clinical Trials as Topic--statistics & numerical data<br/>Combined Modality Therapy<br/>Cytarabine--administration & dosage<br/>Deoxycytidine--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Drugs, Investigational--therapeutic use<br/>Follow-Up Studies<br/>Humans<br/>Ifosfamide--administration & dosage<br/>Immunologic Factors--therapeutic use<br/>Lenalidomide<br/>Lymphoma, T-Cell, Peripheral--drug therapy<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Polyethylene Glycols--administration & dosage<br/>Prednisone--administration & dosage<br/>Remission Induction<br/>Salvage Therapy<br/>Thalidomide--analogs & derivatives<br/>Vinblastine--administration & dosage<br/>Vinorelbine<br/>Gemcitabine